ACORDA THERAPEUTICS INC (ACOR)

US00484M7002 - Common Stock

13.211  +1.3 (+10.92%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACORDA THERAPEUTICS INC

NASDAQ:ACOR (3/28/2024, 8:00:00 PM)

13.211

+1.3 (+10.92%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap16.38M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACOR Daily chart

Company Profile

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Pearl River, New York and currently employs 111 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Company Info

ACORDA THERAPEUTICS INC

Two Blue Hill Plaza

Pearl River NEW YORK 10502

P: 19143474300

CEO: Ron Cohen

Employees: 111

Website: https://www.acorda.com/

ACOR News

News Image3 days ago - Acorda TherapeuticsAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
News Image3 months ago - Seeking AlphaAcorda to regain global commercialization rights to FAMPYRA by Jan 2025 (NASDAQ:ACOR)

Acorda Therapeutics announced it will regain global commercialization rights to FAMPYRA, a treatment for multiple sclerosis, following the termination of...

News Image3 months ago - Acorda TherapeuticsAcorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
News Image5 months ago - Acorda TherapeuticsAcorda Therapeutics Reports Third Quarter 2023 Financial Results
News Image5 months ago - Acorda TherapeuticsAcorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
News Image5 months ago - Acorda TherapeuticsAcorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®

ACOR Twits

Here you can normally see the latest stock twits on ACOR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example